Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GELS
GELS logo

GELS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.785
Open
0.711
VWAP
0.75
Vol
11.24K
Mkt Cap
8.35M
Low
0.711
Amount
8.38K
EV/EBITDA(TTM)
--
Total Shares
10.71M
EV
10.48M
EV/OCF(TTM)
--
P/S(TTM)
66.27
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Show More

Events Timeline

(ET)
2026-02-11
09:00:00
Gelteq and Healthy Extracts Sign Strategic Partnership MOU
select
2026-01-13 (ET)
2026-01-13
09:20:00
Gelteq Oral Gel Platform Increases CBD Bioavailability by Over 22%
select
2025-12-16 (ET)
2025-12-16
09:20:00
Gelteq Announces New Partnership with Hong Kong Flag Football Program
select
2025-12-09 (ET)
2025-12-09
09:20:00
Gelteq Enters Three-Year Sales Agreement with Shenzhen Mana, Expected Revenue of $1.3 Million
select
2025-12-05 (ET)
2025-12-05
10:50:00
Gelteq Announces Preclinical Findings Demonstrating Effectiveness of Gel Platform
select
2025-11-24 (ET)
2025-11-24
08:43:18
Gelteq Reports Encouraging Preclinical Findings for Its Gel Formula
select
2025-10-23 (ET)
2025-10-23
09:09:32
Gelteq Launches Preclinical Trial for Drugs with Low Solubility
select
2025-10-09 (ET)
2025-10-09
08:15:45
Gelteq Partners with Melbourne Health for Product Development and Profit Sharing Agreement
select
2025-09-12 (ET)
2025-09-12
07:32:16
Gelteq Fuels Healthy Extracts' Product Launches in the U.S.
select
2025-07-17 (ET)
2025-07-17
08:36:25
Gelteq announces agreement with IDT Australia to secure manufacturing facility
select

News

Benzinga
8.5
01-14Benzinga
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
  • Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
  • Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
  • Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
  • Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
Benzinga
4.5
01-14Benzinga
U.S. Stock Futures Decline as CPI Rises 2.7% Year Over Year
  • CPI Data Release: The U.S. Consumer Price Index rose 2.7% year over year in December, matching both the previous reading and economists' estimates, indicating persistent inflationary pressures that could influence Federal Reserve policy decisions.
  • Weak Market Performance: The Dow Jones fell by 0.15%, while the S&P 500 and Nasdaq 100 declined by 0.16% each, reflecting investor concerns over future economic growth, which may lead to further deterioration in market sentiment.
  • Bond Yield Dynamics: The 10-year Treasury bond yielded 4.17%, while the two-year bond yielded 3.52%, indicating market expectations for unchanged interest rates, which could impact investors' asset allocation strategies.
  • Analyst Outlook: Professor Jeremy Siegel anticipates robust economic growth in 2026, emphasizing that small-cap and non-tech cyclical stocks will benefit from expected Federal Reserve rate cuts, advising investors to broaden their portfolios to capture opportunities in global markets.
Benzinga
9.5
01-14Benzinga
Bank of America Expected to Report $0.96 EPS on $27.87 Billion Revenue
  • Bank of America Earnings Forecast: Wall Street anticipates Bank of America (BAC) will report quarterly earnings of $0.96 per share and revenue of $27.87 billion before the market opens, with shares slipping 0.1% to $54.51 in after-hours trading, indicating cautious investor sentiment.
  • TG Therapeutics Optimistic Outlook: TG Therapeutics (TGTX) expects Briumvi U.S. net product revenue to reach approximately $182 million for Q4 2025 and total global revenue of about $616 million for the full year, reflecting strong market potential, with shares showing positive movement in after-hours trading.
  • Citigroup Earnings Expectations: Analysts forecast Citigroup (C) will post quarterly earnings of $1.68 per share on revenue of $20.53 billion before the market opens, although shares fell 0.1% to $116.15 in after-hours trading, highlighting investor focus on its upcoming performance.
  • Gelteq Ltd Positive Results: Gelteq Ltd (GELS) reported encouraging preclinical results for its cannabinoid oral gel delivery platform, leading to a 69.3% surge in shares to $1.41 in after-hours trading, indicating strong market interest in its innovative product.
Benzinga
8.5
01-14Benzinga
Gelteq Ltd. (NASDAQ:GELS) Shares Surge 69.25% on Positive Preclinical Results
  • Enhanced Bioavailability: Gelteq's oral gel platform achieved over a 22% increase in CBD bioavailability compared to an FDA-approved oil-based product, indicating a stronger competitive edge in the market.
  • Market Access Opportunity: The company plans to leverage Australia's Special Access Scheme for quicker market entry, enabling earlier patient access to its products and significantly enhancing market potential and revenue prospects.
  • Increased Partnership Opportunities: The study results may facilitate partnerships with medicinal cannabis companies without the need for additional studies, thereby accelerating licensing, white-label manufacturing, and co-development of cannabinoid products, expanding business scope.
  • Market Performance Analysis: Despite a 58.76% decline in GELS stock over the past 12 months, the recent 6.44% increase suggests short-term recovery signs, prompting investors to monitor changes in its long-term trend.
Globenewswire
7.5
2025-12-16Globenewswire
Gelteq Partners with Hong Kong Flag Football Program, Secures $1.3M Annual Revenue Commitment
  • Partnership Announcement: Gelteq's collaboration with the Hong Kong Flag Football Program integrates its advanced hydration and sports performance formulations into national team training, highlighting the growing interest in high-performance sports initiatives in the region.
  • Sales Agreement: The recently established sales agreement with Shenzhen Mana Health Management includes a minimum annual order commitment of $1.3 million, demonstrating Gelteq's increasing commercial adoption in the Southeast Asian market.
  • Technology Utilization: Gelteq's gel-based formulations are designed to support athletes in managing hydration, energy regulation, and recovery, and are already widely used in elite programs across Australia and Asia, enhancing athlete performance.
  • Market Potential: With flag football set to debut at the 2028 Summer Olympics, Gelteq's technology will help Hong Kong athletes build competitive momentum in Asia, further driving the company's expansion in the high-growth global sports sector.
Newsfilter
7.5
2025-12-16Newsfilter
Gelteq Partners with Hong Kong Flag Football Program, Securing $1.3M Annual Revenue
  • Partnership Announcement: Gelteq's new collaboration with the Hong Kong Flag Football Program integrates its advanced hydration and sports performance formulations into national team training, enhancing athlete performance and recovery.
  • Growing Market Demand: This partnership underscores the increasing demand for convenient, research-driven sports nutrition products across Southeast Asia, demonstrating Gelteq's expanding commercial adoption of its proprietary technology in both sports and wellness applications.
  • Sales Agreement: The recently signed sales agreement with Shenzhen Mana Health Management Co. Ltd. includes minimum annual order commitments totaling at least $1.3 million, further solidifying Gelteq's market position in the Asia-Pacific region.
  • Investment in Sports Science: As flag football rapidly grows as a team sport, attracting more investment and attention, Gelteq's technology will support Hong Kong's national teams in enhancing their competitiveness ahead of the 2028 Summer Olympics.

Valuation Metrics

The current forward P/E ratio for Gelteq Ltd (GELS.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Gelteq Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding GELS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Gelteq Ltd (GELS) stock price today?

The current price of GELS is 0.7401 USD — it has decreased -0.13

What is Gelteq Ltd (GELS)'s business?

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

What is the price predicton of GELS Stock?

Wall Street analysts forecast GELS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GELS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Gelteq Ltd (GELS)'s revenue for the last quarter?

Gelteq Ltd revenue for the last quarter amounts to 0.00 USD, decreased

What is Gelteq Ltd (GELS)'s earnings per share (EPS) for the last quarter?

Gelteq Ltd. EPS for the last quarter amounts to -0.12 USD, increased 20.00

How many employees does Gelteq Ltd (GELS). have?

Gelteq Ltd (GELS) has 7 emplpoyees as of March 12 2026.

What is Gelteq Ltd (GELS) market cap?

Today GELS has the market capitalization of 8.35M USD.